National Academy of Sciences | 150 Year Anniversary

Questions? Call 800-624-6242

| Items in cart [0]

The National Academies Press

PAPERBACK
price:$43.50
add to cart

Rights & Permissions

topleft topright

New Vaccine Development: Establishing Priorities: Volume II, Diseases of Importance in Developing Countries (1986)
Board on Population Health and Public Health Practice (BPH)

Citation Manager

. "Appendix D-10: The Prospects for Immunizing Against Plasmodium spp.." New Vaccine Development: Establishing Priorities: Volume II, Diseases of Importance in Developing Countries. Washington, DC: The National Academies Press, 1986.

Please select a format:

BibTeX EndNote RefMan


Page
286
bottomleft bottomright

The following HTML text is provided to enhance online readability. Many aspects of typography translate only awkwardly to HTML. Please use the page image as the authoritative form to ensure accuracy.


New Vaccine Development: Establishing Priorities, Volume II, Diseases of Importance in Developing Countries

Nardin, E.H., R.S.Nussenzweig, I.A.McGregor, and J.H.Bryan. 1979. Antibodies to sporozoites: their frequent occurrence in individuals living in an area of hyperendemic malaria. Science 206:597–599.

Norrby, E. 1985. Summary. Pp. 387–394 in Vaccines 85. Molecular and Chemical Basis of Resistance to Parasitic, Bacterial, and Viral Diseases, R.A.Lerner, R.M.Chanock, and F.Brown, eds. Cold Spring Harbor, N.Y.: Cold Spring Harbor Laboratories.

Nussenszweig, R.S., J.Vanderberg, and H.Most. 1969. Protective immunity produced by the injection of X-irradiated sporozoites of Plasmodium, berghei IV. Dose response, specificity and humoral antibody. Mil. Med. 134(suppl.):1176–1182.

Nussenszweig, R.S., F.Zavala, and V.Nussensweig. 1985. The tandem repeats of the circumsporozoite (CS) protein as a basis for malaria vaccine development. Paper presented at the conference on Modern Approaches to Vaccines, Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y., Sept. 11–15, 1985.


Perrin, L., A.Perez, and C.Chizzolini. 1984. Malaria, immunity, vaccination and immunodiagnosis. Experimentia 40:1343–1350.

Population Reference Bureau. 1984. 1984 World Population Data Sheet. Washington, D.C.: Population Reference Bureau.


Ravetch, J.V., J.Young, and G.Poste. 1985. Molecular genetic strategies for the development of anti-malarial vaccines. Biotechnology 3:729–740.

Reisberg, B. 1980. Malaria. Pp. 707–716 in The Biologic and Clinical Basis of Infectious Diseases, G.P.Youmans, P.Y.Paterson, and H.M. Sommers, eds. Philadelphia: W.B.Saunders.


Smith, G.L., G.N.Godson, V.Nussenszweig, R.S.Nussenszweig, J. Barnwell, and B.Moss. 1984. Expression of antigenic and iminunogenic Plasmodium knowlesi circumsporozoite protein by an infectious vaccinia virus recombinant. Science 224:397–399.

SPRTTD (Special Programme for Research and Training in Tropical Diseases). 1985. Tropical Disease Research. Seventh Programme Report, 1 January 1983–31 December 1984. Geneva: World Health Organization.

Stürchler, D. 1984. Malaria prophylaxis in travellers: The current position. Experientia 40:1357–1362.


Traeger, W., and T.B.Jensen. 1976. Human malaria parasites in continuous culture. Science 193:673–675.


Walsh, J. 1985. Personal communication, Harvard Medical School, Boston, Mass.

World Health Organization. 1984. World malaria situation, 1982. Rapp. Trimest. Statist. Sanit. Mond. 37:130–161.

Wyler, D.J. 1983. Malaria: Resurgence, resistance and research. N. Engl. J. Med. 308:875–878.


Young, J.F., W.T.Hockmeyer, M.Gross, W.R.Ballou, R.A.Wirtz, J.H.Trosper, R.L.Beaudoin, M.R.Hollingdale, L.H.Miller, C.L. Diggs, and M.Rosenberg. 1985. Expression of Plasmodium falciparum circumsporozoite proteins in Escherichia coli for potential use in a human malaria vaccine. Science 228:958–962.

Page
286
Front Matter (R1-R16)
1. Summary (1-18)
2. Priority Setting for Health-Related Investments: A Review of Methods (19-29)
3. Overview of the Analytic Approach (30-43)
4. Comparison of Disease Burdens (44-62)
5. Predictions of Vaccine Development (63-75)
6. Assessing the Likely Utilization of New Vaccines (76-81)
7. Calculation and Comparison of the Health Benefits and Differential Costs Associated with Candidate Vaccines (82-105)
8. Additional Issues in the Selection of Priorities for Accelerated Vaccine Development (106-120)
9. Findings, Conclusions, and Recommendations (121-142)
Appendix A: Selection of Vaccine Candidates for Accelerated Development (143-148)
Appendix B: The Burden of Disease Resulting from Acute Respiratory Illness (149-158)
Appendix C: The Burden of Disease Resulting from Diarrhea (159-169)
Appendix D-1: The Prospects for Immunizing Against Dengue Virus (170-177)
Appendix D-2: The Prospects for Immunizing Against Escherichia coli (178-185)
Appendix D-3: The Prospects for Immunizing Against Hemophilus influenzae Type b (186-196)
Appendix D-4: The Prospects for Immunizing Against Hepatitis A Virus (197-207)
Appendix D-5: The Prospects for Immunizing Against Hepatitis B Virus (208-222)
Appendix D-6: The Prospects for Immunizing Against Japanese Encephalitis Virus (223-240)
Appendix D-7: The Prospects for Immunizing Against Mycobacterium leprae (241-250)
Appendix D-8: The Prospects for Immunizing Against Neisseria meningitidis (251-266)
Appendix D-9: The Prospects for Immunizing Against Parainfluenza Viruses (267-274)
Appendix D-10: The Prospects for Immunizing Against Plasmodium spp. (275-286)
Appendix D-11: The Prospects for Immunizing Against Rabies Virus (287-298)
Appendix D-12: The Prospects for Immunizing Against Respiratory Syncytial Virus (299-307)
Appendix D-13: The Prospects for Immunizing Against Rotavirus (308-318)
Appendix D-14: The Prospects for Immunizing Against Salmonella typhi (319-328)
Appendix D-15: The Prospects for Immunizing Against Shigella spp. (329-337)
Appendix D-16: The Prospects for Immunizing Against Streptococcus Group A (338-356)
Appendix D-17: The Prospects for Immunizing Against Streptococcus pneumoniae (357-375)
Appendix D-18: The Prospects for Immunizing Against Vibrio cholerae (376-389)
Appendix D-19: The Prospects for Immunizing Against Yellow Fever (390-402)
Appendix E: Questionnaire for Assessing Morbidity-Mortality Trade-Offs (403-411)
Appendix F: Technical Notes (412-412)
Appendix G: Biographical Notes on Committee Members (413-417)
Appendix H: Additional Sources of Advice to the Committee (418-419)
Appendix I: Contents of Supplement to Volume II (420-420)
Appendix J: Preface to Volume I (421-422)
Appendix K: Contents to Volume I (423-423)
Index (424-432)